Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor

Blood

Volumn 105, Issue 5, 2005, Pages 1970-1976

  Gallicchio, Margherita ^a   Mitola, Stefania ^b   Valdembri, Donatella ^b   Fantozzi, Roberto ^b   Varnum, Brian ^b   Avanzi, Gian Carlo ^b   Bussolino, Federico ^b  

^a Pharmacology and Forensic Medicine   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE DERIVATIVE; GROWTH ARREST SPECIFIC PROTEIN 6; MATRIGEL; PHOSPHOTYROSINE; PROTEIN AX1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SERINE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; AXL RECEPTOR TYROSINE KINASE; GAS6 PROTEIN, HUMAN; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CELL MATURATION; CHEMOTAXIS; CHORION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MORPHOGENESIS; MUTANT; NEGATIVE FEEDBACK; PRIORITY JOURNAL; VASCULARIZATION; ANIMAL; CHICK EMBRYO; CYTOLOGY; DRUG ANTAGONISM; FEEDBACK SYSTEM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CHEMOTAXIS; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; FEEDBACK, BIOCHEMICAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; ONCOGENE PROTEINS; RECEPTOR CROSS-TALK; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 14944350367     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1469     Document Type: Article

References (80)

1. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991:11:5016-5031.
2. Lai C, Gore M, Lemke G. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene. 1994;9:2567-2578.
3. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 1994;5:647-657.
4. Avanzi GC, Gallicchio M, Bottarel F, et al. GAS6 inhibits granulocyte adhesion to endothelial cells. Blood. 1998:91:2334-2340.
5. Nakano T. Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J. 1997;323:387-392.
6. Lu Q, Gore M, Zhang Q, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature. 1999;398:723-728.
7. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol. 1995:15:614-625.
8. Lu W, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306-311.
9. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993;13:4976-4985.
10. Ohashi K, Nagata K, Toshima J, et al. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem. 1995;270:22681-22684.
11. Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem. 1996;271:30022-30027.
12. Varnum BC, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 1995;373:623-626.
13. McCloskey P, Fridell YW, Attar E, et al. GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem. 1997;272:23285-23291.
14. Yanagita M, Aral H, Nakano T, et al. Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem. 2001;276:42364-42369.
15. Bellosta P, Zhang Q, Goff SP, Basilico C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene. 1997;15:2387-2397.
16. D'Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res. 2002;91:e4-12.
17. Goruppi S, Ruaro E, Varnum B, Schneider C. Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras. Oncogene. 1999;18:4224-4236.
18. O'Donnell K. Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol. 1999;154:1171-1180.
19. Allen MP, Linseman DA, Udo H, et al. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Mol Cell Biol. 2002;22:599-613.
20. Fridell YW, Villa J Jr. Attar EC, Liu ET. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem. 1998;273:7123-7126.
21. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7:215-221.
22. Nakano T, Higashino K, Kikuchi N, et al. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem. 1995;270:5702-5705.
23. Collett G, Wood A, Alexander MY, et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res. 2003;92:1123-1129.
24. Melaragno MG, Wuthrich DA, Poppa V, et al. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res. 1998;83:697-704.
25. Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today. 1997;18:231-239.
26. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
27. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
28. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
30. Bussolino F, Di Renzo MF, Ziehe M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629-641.
31. Primo L, Roca C, Ferrandi C, Lanfrancone L, Bussolino F. Human endothelial cells expressing polyoma middle T induce tumors. Oncogene. 2000;19:3632-3641.
32. Zhao Z, Tan Z, Wright J, et al. Altered expression of protein-tyrosine phosphatase 2C in 293 cells affects protein tyrosine phosphorylation and mitogen-activated protein kinase activation. J Biol Chem. 1995;270:11765-11769.
33. Cutrupi S, Baldanzi G, Gramaglia D, et al. Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility. EMBO J. 2000;19:4614-4622.
34. Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol. 2001;166:3890-3899.
35. Roca C, Primo L, Valdembri D, et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res. 2003;63:1500-1507.
36. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 2002;16:225-227.
37. Sgadari C, Bacillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med. 2002;8:225-232.
38. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882-892.
39. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med. 1996;2:1371-1375.
40. Ylikorkala A, Rossi DJ, Korsisaari N, et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 2001;293:1323-1326.
41. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn. 2001;220:1-17.
42. Serini G, Ambrosi D, Giraudo E, Gamba A, Preziosi L, Bussolino F. Modeling the early stages of vascular network assembly. EMBO J. 2003;22:1771-1779.
43. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271:603-606.
44. Feng G. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res. 1999;253:47-54.
45. Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol. 2001;13:182-195.
46. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272:32521-32527.
47. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun. 2002;290:197-203.
48. Melaragno MG, Fridell YW, Berk BC. The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med. 1999;9:250-253.
49. Fiebeler A, Park JK, Muller DN, et al. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis. 2004;43:286-295.
50. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer. 2001;37:2264-2274.
51. Sun WS, Misao R, Iwagaki S, Fujimoto J, Tamaya T. Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases, Axl and Sky, in human uterine endometrium and ovarian endometriosis. Mol Hum Reprod. 2002;8:552-558.
52. Bagowski CP, Stein-Gerlach M, Choidas A, Ullrich A. Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor. EMBO J. 1999;18:5567-5576.
53. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol. 2000;2:62-69.
54. Mothe I, Ballotti R, Tartare S, Kowalski-Chauvel A, Van Obberghen E. Cross talk among tyrosine kinase receptors in PC12 cells: desensitization of mitogenic epidermal growth factor receptors by the neurotrophic factors, nerve growth factor and basic fibroblast growth factor. Mol Biol Cell. 1993;4:737-746.
55. Amselgruber WM, Schafer M, Sinowatz F. Angiogenesis in the bovine corpus luteum: an immunocytochemical and ultrastructural study. Anat Histol Embryol. 1999;28:157-166.
56. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314:15-23.
57. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
58. Tulis DA, Mnjoyan ZH, Schiesser RL, et al. Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration. Circulation. 2003;107:98-105.
59. Cossette LJ, Hoglinger O, Mou L, Shen SH. Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells. Exp Cell Res. 1996;223:459-466.
60. Yu CF, Liu ZX, Cantley LG. ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem. 2002;277:19382-19388.
61. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science. 1996;272:1170-1173.
62. Doan T, Farmer P, Cooney T, Ali MS. Selective down-regulation of angiotensin II receptor type 1A signaling by protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells. Cell Signal. 2004;16:301-311.
63. Hanafusa H, Torii S, Yasunaga T, Matsumoto K, Nishida E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem. 2004;279:22992-22995.
64. Milarski KL, Saltiel AR. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J Biol Chem. 1994;269:21239-21243.
65. Xiao S, Rose DW, Sasaoka T, et al. Syp (SHPTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem. 1994;269:21244-21248.
66. Kim H, Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol. 1999;19:5326-5338.
67. Yu CL, Jin YJ, Burakoff SJ. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J Biol Chem. 2000;275:599-604.
68. Guo DQ, Wu LW, Dunbar JD, et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem. 2000;275:11216-11221.
69. Seo D, Li H, Guedez L, et al. TIMP-2 mediated angiogenesis: am MMP-independent mechanisms. Cell. 2003;114:171-180.
70. Huang L, Sankar S, Lin C, et al. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem. 1999;274:38183-38188.
71. Saxton TM, Henkemeyer M, Gasca S, et al. Abnormal mesoderm pattering in mouse embryo mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 1997;16:2352-2364.
72. Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration and focal adhesion. J Biol Chem. 1998;273:21125-21131.
73. Manes S, Mira E, Gomez-Mouton C, Zhao ZJ, Lacalle RA, Martinez AC. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol. 1999;19:3125-3135.
74. von Wichert G, Haimovich B, Feng G, Sheetz M. Force-dependent integrin-cytoskeleton linkage formation requires downregulation of focal complex dynamics by Shp-2. EMBO J. 2003;22:5023-5035.
75. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
76. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci. 1997;22:251-256.
77. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591-1598.
78. Kalluri R. Basement membranes: structures, assembly and role in tumor angiogenesis. Nat Rev Cancer. 2003;3:422-433.
79. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
80. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.